Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.50 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.50 |
| ▸ | PPARG | P37231 | 9/20 | 0.49 |
| ▸ | PPARA | Q07869 | 7/20 | 0.49 |
| ▸ | PPARD | Q03181 | 1/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.47 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.47 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.46 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.46 |
| ▸ | FABP1 | P07148 | 1/20 | 0.45 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.45 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4885499 | 0.98 | FFAR4 (0.50) | FFAR4FFAR1PPARGPPARAPPARD | |
| SCHEMBL4896559 | 0.94 | PPARG (0.52) | FFAR4FFAR1PPARGPPARAHDAC1 | |
| SCHEMBL4888272 | 0.92 | PPARG (0.52) | FFAR4FFAR1PPARGPPARAPPARD | |
| SCHEMBL4898434 | 0.89 | PPARG (0.51) | FFAR4FFAR1PPARGPPARAPPARD | |
| SCHEMBL4888371 | 0.87 | PPARG (0.51) | FFAR4FFAR1PPARGPPARAPPARD | |
| SCHEMBL4897935 | 0.87 | PPARG (0.48) | FFAR4FFAR1PPARGPPARAHDAC1 | |
| SCHEMBL4893180 | 0.86 | PPARG (0.51) | FFAR4FFAR1PPARGPPARAPPARD | |
| SCHEMBL4895315 | 0.85 | PPARG (0.48) | FFAR4FFAR1PPARGPPARAHDAC1 | |
| SCHEMBL4898849 | 0.85 | PPARG (0.44) | FFAR4FFAR1PPARGPPARAHDAC1 | |
| SCHEMBL4888233 | 0.84 | PPARG (0.49) | FFAR4FFAR1PPARGPPARAPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080167310-A1 | MODULATORS OF PEROXISOME PROLIFERATOR ACTIVATED RECEPTORS (PPAR) | GOSSETT LYNN STACY | 2008-07-10 | — | — | US | disclosed |
| US-20080167310-A1 | MODULATORS OF PEROXISOME PROLIFERATOR ACTIVATED RECEPTORS (PPAR) | GOSSETT LYNN STACY | 2008-07-10 | — | — | US | disclosed |
| US-20080167310-A1 | MODULATORS OF PEROXISOME PROLIFERATOR ACTIVATED RECEPTORS (PPAR) | GOSSETT LYNN STACY | 2008-07-10 | — | — | US | disclosed |
| US-7282501-B2 | Modulators of peroxisome proliferator activated receptors (PPAR) | ELI LILLY AND COMPANY (US) | 2007-10-16 | — | — | US | disclosed |
| US-7282501-B2 | Modulators of peroxisome proliferator activated receptors (PPAR) | ELI LILLY AND COMPANY (US) | 2007-10-16 | — | — | US | disclosed |
| US-7282501-B2 | Modulators of peroxisome proliferator activated receptors (PPAR) | ELI LILLY AND COMPANY (US) | 2007-10-16 | — | — | US | disclosed |
| US-20050075378-A1 | Modulators of peroxisome proliferator activated receptors (ppar) | ELI LILLY AND COMPANY | 2005-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050075378-A1 | Modulators of peroxisome proliferator activated receptors (ppar) | PPARG, PPARA, PPARD | FFAR4 16/4885FFAR1 10/4885PPARG 1/4885 |
| US-20080167310-A1 | MODULATORS OF PEROXISOME PROLIFERATOR ACTIVATED RECEPTORS (PPAR) | PPARG, PPARA, PPARD | FFAR4 16/4885FFAR1 10/4885PPARG 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.